ALK GENE REARRANGEMENT
Clinical trials for ALK GENE REARRANGEMENT explained in plain language.
Never miss a new study
Get alerted when new ALK GENE REARRANGEMENT trials appear
Sign up with your email to follow new studies for ALK GENE REARRANGEMENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted pill may keep ALK-Positive lung cancer from returning after surgery
Disease control OngoingThis study tests whether taking crizotinib after surgery can prevent early-stage non-small cell lung cancer from coming back in people whose tumors have a specific ALK gene change. About 166 participants who had their cancer completely removed will either take crizotinib or just …
Matched conditions: ALK GENE REARRANGEMENT
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo attack on hard-to-treat lung cancer shows early promise
Disease control OngoingThis early trial tested a two-pronged approach for people with advanced ALK-positive non-small cell lung cancer. Participants first received a targeted drug (brigatinib), then local treatments like surgery or radiation to any remaining tumors. The goal was to see if this combinat…
Matched conditions: ALK GENE REARRANGEMENT
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New combo therapy shows promise for tough lung cancers
Disease control OngoingThis early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The study includes 21 participants and aims…
Matched conditions: ALK GENE REARRANGEMENT
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:54 UTC